Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

Impact · against what's priced in

Eli Lilly, Novo Nordisk, and Pfizer gain a significant competitive advantage via three-year tariff exemptions, despite required price reductions. While generic drug importers face a massive cost shock starting in 2028, these branded leaders have secured immediate cost certainty and a strategic moat against tariff-driven input inflation.

LLY+0.40: No priced-in read yet

Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

What matters in this story

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

What matters in this story

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

How each ticker is affected

Connected tickers

Track these names every morning.

Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?

Cramer's week ahead: Expect more volatility as tech earnings, midterms loom

MGM Resorts: Vegas Weakness Hurts Earnings, But Valuation Keeps Us Bullish

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

What matters in this story

Next reads from the same story arc

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

What matters in this story

Next reads from the same story arc

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

How each ticker is affected

Connected tickers

Track these names every morning.

Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?

Cramer's week ahead: Expect more volatility as tech earnings, midterms loom

MGM Resorts: Vegas Weakness Hurts Earnings, But Valuation Keeps Us Bullish

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit